Bharat Book Bureau

With rapidly increasing urbanization and economic liberalization, the criminal activities at different levels of the society have become a common practice in India. Moreover, the growing incidences of terrorist attacks have significantly changed the perception of Indian consumer for better and advanced safety and security needs. The frightening terrorist attack in Mumbai on November 26, 2008 indicates to a clear need of deploying and upgrading security equipments to modern and hi-tech across the country.

Closed Circuit Television (CCTV) has emerged as the most viable solution for security surveillance in the Indian electronic security market, says our latest research report “Indian CCTV Market Analysis”. The research has estimated that the Indian electronics security market valued around Rs. 1600 Crore in 2008 and CCTV accounted for more than a third of this market. This segment has been growing at a much faster rate than other segments such as access control, intrusion alarm or fire detection alarm.

Our end-user analysis points out that at present the government/public sector demand remains high for overall security systems followed by industrial and commercial sector. However, it is found that the demand for electronics security systems from residential sector will outpace the growth in other end-users segments. Special events such as Commonwealth Games 2010 will also add growth to the Indian CCTV market, which is forecasted to grow at a CAGR of more than 34% during 2010-2012.

“Indian CCTV Market Analysis” contains an extensive research and rational analysis of the CCTV market in India. It offers comprehensive study of the factors which are driving up the demand for CCTV surveillance systems in the country coupled with the steps taken by the government to deal deal with security threats. The report briefly explains the electronic security market demand across various end-user segments and how is it important for the CCTV players. Besides, the report talks about key geographical market where demand for surveillance systems will boom in near future along with analysis of key players in the Indian CCTV market.

Table of Contents:

1. Analyst View
2. Indian Electronic Security Market Overview
2.1 Market Segmentation
3. CCTV Market Analysis
3.1 Current Market Size
3.2 Future Outlook
3.3 Key Market Trends and Developments
3.3.1 Emerging Security Needs
3.3.2 Focus on IP-based Surveillance
3.3.3 Technological Innovation
3.3.4 Declining Cost
4. End-user Analysis
4.1 Public Sector
4.2 Industrial Sector
4.3 Commercial Sector
4.4 Residential Sector
4.5 Retail Sector
5. Major Geographical Markets
6. Growth Inhibitors

List of Figures:

Figure 2-1: Electronic Security Market (Crore Rs), 2008 & 2009
Figure 2-2: Forecast for Electronic Security Market (Crore Rs), 2010-2012
Figure 2-3: Electronic Security Market by Product (%), 2008
Figure 2-4: Electronic Security Market by End-user (%), 2008
Figure 2-5: Forecast for Electronic Security Market by Product (%), 2012
Figure 2-6: Forecast for Electronic Security Market by End-user (%), 2012
Figure 3-1: CCTV Surveillance Market (Crore Rs), 2008 & 2009
Figure 3-2: Forecast for CCTV Surveillance Market (Crore Rs), 2010-2012
Figure 4-1: Public Sector Demand for Electronic Security Market (Crore Rs), 2008 & 2012
Figure 4-2: Industrial Sector Demand for Electronic Security Market (Crore Rs), 2008 & 2012
Figure 4-3: Commercial Sector Demand for Electronic Security Market (Crore Rs), 2008 & 2012
Figure 4-4: Residential Sector Demand for Electronic Security Market (Crore Rs), 2008 & 2012
Figure 4-5: Retail Sector Demand for Electronic Security Market (Crore Rs), 2008 & 2012

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Indian-CCTV-Market-Analysis.html

Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses

Pharmaceutical consumption in India is expected to grow substantially over the next five years, driven by a rise in disposable income, an ageing population and improving medical infrastructure. These growth drivers have led to India becoming a major emerging location for global pharma companies, however ongoing problems such as frequent power cuts, an insufficient transport infrastructure and gaps in the new patent regime may slowdown the sector’s development. ‘The Top 10 Pharmaceutical Companies in India’ is a new report published by Business Insights that explores the global competitive landscape of the Indian pharma market. The key drivers and resistors of market growth are identified, and the major trends and competitive dynamics are analyzed. The top 10 pharma companies in India are identified, and each company is assessed based on their marketed products, therapeutic focus and key growth strategies. The business-related strengths and weaknesses of the top 10 companies are also evaluated, and insights are provided into the opportunities and threats they face in the future.

Table of Contents:

Executive summary 12
Industry overview 12
Cipla 13
Ranbaxy 13
GSK (India) 14
Piramal Healthcare 14
Zydus Cadila 15
Sun Pharma 15
Lupin Laboratories (Lupin) 16
Alkem 16
Sanofi-Aventis (India) 17
Mankind Pharma (Mankind) 17

Chapter 1 Introduction 20
What is this report about? 20
Methodology 20

Chapter 2 Industry overview 24
Summary 24
Introduction 25
Market dynamics 25
Indian pharmaceutical market: size and growth 25
Key market drivers and resistors 26
India’s adoption of product patent regime 27
Evolution of biopharmaceuticals in India 28
Competitive positioning of India in global pharmaceutical market 30
Competitive landscape 32
Competitive positioning of the top 10 companies 32
Exposure to US generics market 35
Comparative analysis of the top 10 companies 36
Trends 37
Increasing participation of innovator companies in Indian pharmaceutical
space 37
Pharmaceutical companies making inroads into rural India 38
Shifting focus towards Japanese generics market 39
Growing prevalence of lifestyle diseases 40
Expanding alliances in biopharmaceuticals 41

Chapter 3 Cipla 46
Summary 46
Company overview 47
Marketed products 47
Therapeutic focus 49
Research and development 49
Growth strategies 50
Expanding in international markets through alliances and partnerships 50
Expanding capabilities 50
Growing in the US generics market 51
Acquisitions and divestments 51
SWOT analysis 52

Chapter 4 Ranbaxy 54
Summary 54
Company overview 55
Marketed products 56
Therapeutic focus 56
Research and development 57
Growth strategies 58
Rebuilding business in the US market 58
Shifting focus towards complex products in the US 58
Monetizing the FTF opportunities in the US 58
Improving penetration in emerging markets 59
Strengthening management involvement in Ranbaxy 59
Acquisitions and divestments 60
SWOT analysis 61

Chapter 5 GSK (India) 64
Summary 64
Company overview 65
Marketed products 66
Therapeutic focus 66
Research and development 67
Growth strategies 68
Augmenting product portfolio in India 68
Leveraging its parent company’s product portfolio 68
In-licensing products 69
Expanding rural presence and hospital sales 69
Acquisitions and divestments 70
SWOT analysis 71

Chapter 6 Piramal Healthcare 74
Summary 74
Company overview 75
Marketed products 75
Therapeutic focus 77
Research and development 77
Growth strategies 78
Capitalize on contract manufacturing opportunities 78
Growing business through alliances and partnerships 78
Acquisitions and divestments 79
SWOT analysis 81

Chapter 7 Zydus Cadila 84
Summary 84
Company overview 85
Marketed products 86
Therapeutic focus 86
Research and development 87
Growth strategies 88
Alliances fostering growth in international generics markets 88
Sustaining revenue growth in Indian formulation business 89
Acquisitions and divestments 90
SWOT analysis 91

Chapter 8 Sun Pharma 94
Summary 94
Company overview 95
Marketed products 95
Therapeutic focus 97
Research and development 97
Growth strategies 98
Enhancing presence in the US market 98
Focusing on niche segments in developing markets 98
Plugging gaps in its business through investments 99
Acquisitions and divestments 99
SWOT analysis 100

Chapter 9 Lupin 102
Summary 102
Company overview 103
Marketed products 103
Therapeutic focus 104
Research and development 104
Growth strategies 105
Expanding in European markets 105
Foray into biosimilars market 105
Sustaining growth in the US generics market 106
Shifting focus to chronic and specialized products in India 106
Acquisitions and divestments 106
SWOT analysis 108

Chapter 10 Alkem 110
Summary 110
Company overview 111
Marketed products 111
Therapeutic focus 112
Research and development 112
Growth strategies 113
Expanding presence in nutraceuticals business 113
Expansion in international markets 113
Acquisitions and divestments 114
SWOT analysis 114

Chapter 11 Sanofi-Aventis (India) 116
Summary 116
Company overview 117
Marketed products 117
Therapeutic focus 118
Research and development 119
Growth strategies 119
Leveraging parent company’s product portfolio 119
Shifting focus to rural India 120
Acquisitions and divestments 121
SWOT analysis 122

Chapter 12 Mankind 124
Summary 124
Company overview 125
Marketed products 126
Therapeutic focus 126
Research and development 127
Growth strategies 128
Expanding in international markets 128
Investing in pharmaceutical capabilities development 128
Foray into fast growing segments 128
Acquisitions and divestments 129
SWOT analysis 130

Chapter 13 11–20 companies 132
Abbott (India) 132
Company overview 132
Marketed products 133
Therapeutic focus 134
Research and development 134
Dr Reddy’s 135
Company overview 135
Marketed products 136
Therapeutic focus 137
Research and development 138
Wockhardt 139
Company overview 139
Marketed products 140
Therapeutic focus 140
Research and development 141
Aristo 142
Company overview 142
Marketed products 143
Therapeutic focus 144
Torrent Pharmaceuticals (Torrent) 145
Company overview 145
Marketed products 146
Therapeutic focus 147
Research and development 147
Pfizer (India) 148
Company overview 148
Marketed products 149
Therapeutic focus 150
Research and development 151
Intas 151
Company overview 151
Marketed products 152
Therapeutic focus 152
Research and development 153
Alembic 154
Company overview 154
Marketed products 155
Therapeutic focus 155
Research and development 156
FDC 157
Company overview 157
Marketed products 157
Therapeutic focus 158
Research and development 159
Macleods Pharmaceuticals (Macleods) 160
Company overview 160
Marketed products 161
Therapeutic focus 162
Research and development 162

Chapter 14 Appendix 164
Glossary 164
Index 168

List of Figures
Figure 2.1: Indian pharmaceutical market size ($m), 2009–14 26
Figure 2.2: Key market drivers and resistors of Indian pharmaceutical market 27
Figure 2.3: Indian pharmaceutical market SWOT analysis 30
Figure 2.4: Top 10 pharmaceutical companies in India market share, 2008 33
Figure 2.5: Top 10 pharmaceutical companies in India growth, 2004–08 34
Figure 2.6: Comparative analysis of the top Indian pharmaceutical companies 37
Figure 2.7: Top 10 pharmaceutical companies in India lifestyle segment market share (%), 2008 41
Figure 3.8: Cipla therapeutic focus, 2007–08 49
Figure 3.9: Cipla SWOT analysis 52
Figure 4.10: Ranbaxy therapeutic focus, 2007–08 57
Figure 4.11: Ranbaxy SWOT analysis 61
Figure 5.12: GSK (India) therapeutic focus, 2007–08 67
Figure 5.13: GSK (India) SWOT analysis 71
Figure 6.14: Piramal Healthcare therapeutic focus, 2007–08 77
Figure 6.15: Piramal Healthcare SWOT analysis 81
Figure 7.16: Zydus Cadila therapeutic focus, 2007–08 87
Figure 7.17: Zydus Cadila SWOT analysis 91
Figure 8.18: Sun Pharma therapeutic focus, 2007–08 97
Figure 8.19: Sun Pharma SWOT analysis 100
Figure 9.20: Lupin therapeutic focus, 2007–08 104
Figure 9.21: Lupin SWOT analysis 108
Figure 10.22: Alkem therapeutic focus, 2007–08 112
Figure 10.23: Alkem SWOT analysis 114
Figure 11.24: Sanofi-Aventis (India) therapeutic focus, 2007–08 119
Figure 11.25: Sanofi-Aventis (India) SWOT analysis 122
Figure 12.26: Mankind therapeutic focus, 2007–08 127
Figure 12.27: Mankind SWOT analysis 130
Figure 13.28: Abbott (India) therapeutic focus, 2007–08 134
Figure 13.29: Dr Reddy’s therapeutic focus, 2007–08 137
Figure 13.30: Wockhardt therapeutic focus, 2007–08 141
Figure 13.31: Aristo therapeutic focus, 2007–08 144
Figure 13.32: Torrent therapeutic focus, 2007–08 147
Figure 13.33: Pfizer (India) therapeutic focus, 2007–08 150
Figure 13.34: Intas therapeutic focus, 2007–08 153
Figure 13.35: Alembic therapeutic focus, 2007–08 156
Figure 13.36: FDC therapeutic focus, 2007–08 159
Figure 13.37: Macleods therapeutic focus, 2007–08 162

List of Tables
Table 2.1: Indian pharmaceutical market size ($m), 2009–14 25
Table 2.2: Novel product pipeline of select Indian biotechnology companies, 2008 29
Table 2.3: Major foreign acquisitions by Indian pharmaceutical companies, 2007–09 32
Table 2.4: Top 10 pharmaceutical companies in India growth (%), 2004–08 34
Table 2.5: Selected ANDA filings approved in the US, 2009 35
Table 2.6: Deals and alliances in Japanese pharmaceutical market, 2007–09 40
Table 2.7: Selected alliances in the Indian biopharmaceutical market, 2007–09 43
Table 3.8: Cipla snapshot 46
Table 3.9: Cipla top 10 marketed products sales ($m), 2007–08 47
Table 3.10: Cipla new product launches, 2007–08 48
Table 3.11: Approved ANDAs of Cipla in the US, 2007–09 51
Table 4.12: Ranbaxy snapshot 54
Table 4.13: Ranbaxy top 10 marketed products sales in India ($m), 2007–08 56
Table 4.14: Selected Ranbaxy ANDAs with FTF status 59
Table 4.15: Ranbaxy acquisitions, 2007–09 60
Table 5.16: GSK (India) snapshot 64
Table 5.17: GSK (India) top 10 marketed products sales ($m), 2007–08 66
Table 5.18: GSK (India) product launches from parent portfolio, 2007–09 68
Table 5.19: GSK (India) expected new launches in India, 2009–10. 69
Table 6.20: Piramal Healthcare snapshot 74
Table 6.21: Piramal Healthcare top 10 marketed products sales ($m), 2007–08 76
Table 6.22: Piramal Healthcare new product launches, 2007–08 76
Table 6.23: Select Piramal Healthcare’s alliances, 2007–09 79
Table 6.24: Piramal Healthcare acquisitions, 2007–09 80
Table 7.25: Zydus Cadila snapshot 84
Table 7.26: Zydus Cadila top 10 marketed products sales ($m), 2007–08 86
Table 7.27: Zydus Cadila R&D collaborations, 2007–09 88
Table 7.28: Select Zydus Cadila’s alliances, 2005–09 89
Table 7.29: Zydus Cadila acquisitions, 2007–09 90
Table 8.30: Sun Pharma snapshot 94
Table 8.31: Sun Pharma top 10 marketed products sales ($m), 2007–08 95
Table 8.32: Sun Pharma new product launches, 2007–08 96
Table 9.33: Lupin snapshot 102
Table 9.34: Lupin top 10 marketed products sales ($m), 2007–08 103
Table 9.35: Lupin acquisitions, 2007–09 107
Table 10.36: Alkem snapshot 110
Table 10.37: Alkem top 10 marketed products sales ($m), 2007–08 111
Table 11.38: Sanofi-Aventis (India) snapshot 116
Table 11.39: Sanofi-Aventis (India) top 10 marketed products sales ($m), 2007–08 118
Table 11.40: Sanofi-Aventis (India) key brands launches from parent portfolio 120
Table 12.41: Mankind snapshot 124
Table 12.42: Mankind top 10 marketed products sales ($m), 2007–08 126
Table 13.43: Abbott (India) snapshot 132
Table 13.44: Abbott (India) top 10 marketed products sales ($m), 2007–08 133
Table 13.45: Dr Reddy’s snapshot 135
Table 13.46: Dr Reddy’s top 10 marketed products sales ($m), 2007–08 136
Table 13.47: Dr Reddy’s drug development pipeline, 2007–08 138
Table 13.48: Wockhardt snapshot 139
Table 13.49: Wockhardt top 10 marketed products sales ($m), 2007–08 140
Table 13.50: Aristo snapshot 142
Table 13.51: Aristo top 10 marketed products sales ($m), 2007–08 143
Table 13.52: Torrent snapshot 145
Table 13.53: Torrent top 10 marketed products sales ($m), 2007–08 146
Table 13.54: Pfizer (India) snapshot 148
Table 13.55: Pfizer (India) top 10 marketed products sales ($m), 2007–08 149
Table 13.56: Intas snapshot 151
Table 13.57: Intas top 10 marketed products sales ($m), 2007–08 152
Table 13.58: Alembic snapshot 154
Table 13.59: Alembic top 10 marketed products sales ($m), 2007–08 155
Table 13.60: FDC snapshot 157
Table 13.61: FDC top 10 marketed products sales ($m), 2007–08 158
Table 13.62: Selected FDC new product launches, 2007–08 158
Table 13.63: Macleods snapshot 160
Table 13.64: Macleods top 10 marketed products sales($m), 2007–08 161

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/The-Top-10-Pharmaceutical-Companies-in-India-Growth-strategies-performance-and-SWOT-analyses.html

Mitsubishi Electric Corporation and IHI Corporation are undertaking an ambitious project of $ 21bn. They are aspiring to design and develop a Space-based solar farm that would generate 1GW of power. This will require an area of four square kilometer consisting of rows of solar panels. This space solar farm will be housed 36,000km above the surface of the earth.

The idea of generating solar power from space has been gathering momentum for quite some time. And various alternative energy companies are investing substantial amount of money in this concept. The advantages of harnessing solar energy from space are many. Solar energy in space is ten times more than on the planet earth. In space there are no nights and no weather changes. The wear and tear will be less too because of lack of humidity, rain, storm or friction.

This 21bn power project has a timeline of three decades. Before wetting their feet fully, Japan Aerospace Exploration Agency (JAXA) will go for a small 10MW demonstration satellite which would have solar panels. This smaller project would be completed in 2015. This experimental project will first test the water before taking the whole plunge. They will also test the systems used to beam energy from space to ground-based receivers. Once fully developed the plant will generate about 1GW of solar power on the ground. It could be a base load resource instead of an intermittent source of power.

This amount of power can meet the energy needs of about 294,000 Tokyo homes on an average.

In fact base load issues are one the last hurdles when we talk about many forms of renewable energy. But the million dollar question to tackle is how to get the power from the solar panels affixed upon the orbiting platforms back to Earth? Currently the existing knowledge says that one can convert it into radio frequency energy for transmission. We can install a receiving station on the earth, which then converts it back into electricity.

If successful, the pilot project could deal with certain concerns such as the use of environmentally sensitive areas for extensive solar farms. However, they have to tackle one more issue: the energy required to produce and put these solar panels into space versus the amount of energy they may generate. One of the solutions can be that they can utilize the concept of space elevators.

A division of JAXA, the Institute of Space and Astronautical Science (ISAS) has already prepared a prototype of the SPS2000, a 10 megawatt demonstration solar-power satellite.

ISAS is also undertaking a project where an experimental satellite will be tested for wireless power supply of several hundred kilowatts. Ground experiments are being held for scrutinizing the influence of high-voltage discharge which is a sheer necessity for large-capacity power generation in space. They are also spending time on the impact of space debris on the solar farm.

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Solar-Power-India.html

According to the information released by HOT TELECOM  in its latest report “India telecom country profile 2008”, India’s mobile phones now account for 86.9% of the total telephones, after surpassing the number of fixed lines for the first time in 2004. The sector grew by an average rate of 87.7% in the last 5 years to reach 261.1 million subscribers (including GSM, CDMA and WLL) at the end of March 2008, surpassing the US for the first time (in terms of mobile subscribers) and becoming the world’s second largest mobile market after China.

73.7% of the country’s mobile customers are subscribed to GSM and the remainder are CDMA customers. The mobile growth trend is continuing albeit at a slower pace, with the number of mobile customers increasing by 11.8% in the first three months of 2008. The sector’s penetration rate now stands at 23.1%, compared with 2.7% in 2003.

Mobile growth is forecasted to remain in the double digits until the end of the forecasted period, with an average growth rate of 22.8% between 2007 and the end of 2012. At that time, mobile subscribers are forecasted to have reached 643.0 million and a penetration rate of 51.8%. Mobile phones should then represent 94.0% of all telephone connections in India .

This 45-page report, which includes 32 details exhibits and tables on India ’s telecom market, declares that with over 1.1 billion inhabitants and a highly competitive telecom market, India is and will remain one of the world’s most dynamic and promising telecom markets for the next five years, even surpassing China in terms of market vitality. Teledensity has increased close to four-fold in the last five years and service tariffs have gone down substantially. The last five years have witnessed the number of fixed and mobile phones more than quadruple, taking the total number to 300.5 million at the end of March 2008. “Total telecom penetration has increased from 6.6% in 2003 to 26.6% at the end of 1Q 2008, a growth almost entirely generated by the mobile sector” HOT TELECOM’s president Isabelle Paradis said.

For more please visit
http://www.bharatbook.com/Market-Research-Reports/India-country-profile.html

Emerging Biofuel Market in India

The Indian biofuel market has been consistently witnessing growth and developments for past few years. The Government of India is injecting huge amount of money and resources into the development of this sector in an attempt to reduce dependency on imported oil. High volatile oil prices and production levels have further enlightened the need for continuous developments of this sector.

According to our research report “Emerging Biofuel Market in India”, the Indian ethanol consumption is projected to grow at a CAGR of around 4% during 2009-2018.  We have thoroughly discussed various factors contributing to the growth of ethanol consumption in the report. Besides, the trend of high consumption will not be limited to ethanol but biodiesel will also register strong upsurge in consumption in coming years.

Thanks to fluctuating oil prices in the international market and continuously increasing oil import, the Indian biofuel sector is expected to see robust growth in coming years. Currently, ethanol dominates the Indian biofuel sector, but biodiesel will soon join the commercial stream as the phase one of pilot projects has already been completed. Being at the initial stage, but with huge potential in terms of production, the Indian biofuel industry will prove to be a good option for biofuel producers.

“Emerging Biofuel Market in India” provides an extensive information and rational analysis of the Indian biofuel market. It gives a deep insight into ethanol and biodiesel market across the country. Analysis and statistics regarding market size, growth, segmentation and trends in technology developments have been comprehensively discussed in the report to provide clients a clear and precise overview of the concerned market.

Our report also gives forecast for various segments of the Indian biofuel industry based on feasible biofuel industry environment. These include:

- Share in Global Ethanol Production
- Ethanol Share in Gasoline-Type Fuel
- Ethanol Production
- Ethanol Consumption
- Biodiesel Demand
- Potential Market for Flex Fuel Cars

The forecast given in this report is not based on a complex economic model, but is intended as a rough guide to the direction in which the market is likely to move. This forecast is based on correlations between past market growth, growth of base drivers and possible impact of recession on the economy.

Table of Contents:

1. Analyst View
2. Biofuel Overview
3. Indian Biofuel Industry  - In Global Context
3.1 Ethanol
3.2 Biodiesel
4. Why India is Supporting Biofuel?
4.1 Concern for Energy Security
4.2 Automobile Industry
4.3 Global Warming
4.4 Government Initiatives
4.5 Rural Employment
5. Ethanol - Performance
5.1 Current Status
5.1.1 Production
5.1.2 Consumption
5.1.3 Demand
5.1.4 Supply
5.2 Feedstock Analysis
5.2.1 Production
5.2.2 Alternate Feedstock
5.3 Cost Analysis
5.4 Future Outlook
5.4.1 Production
5.4.2 Consumption
6. Biodiesel - Performance
6.1 Current Status
6.1.1 Production
6.1.2 Demand
6.2 Feedstock Analysis
6.2.1 Production
6.2.2 Plantation
6.3 Cost Analysis
6.4 Future Outlook
7. Government Initiatives and Policies
7.1 Ethanol
7.2 Biodiesel
8. Industry Trends
8.1 Potential Market for Flex-fuel Vehicles
8.2 Biofuel in Mobile Networks
8.3 Biotechnology and Biofuel
8.4 Glycerol Industry
8.5 Availability of Molasses
8.6 Price Fluctuation of Raw Material

List of Figures:

Figure 3-1: Global - Biofuel Market (Billion US$), 2005-2008
Figure 3-2: Global - Ethanol Production (Million Gallon), 2004-2008
Figure 3-3: Global - Biodiesel Production (Million Gallon), 2004-2008
Figure 3-4: Global - Biodiesel Production by Region (%), 2008
Figure 4-1: Crude Oil Import (‘000 Metric Tons), 2003-04 to 2008-09
Figure 4-2: Domestic Vehicle Sales (Million Units), 2002-03 to 2008-09
Figure 4-3: High Speed Diesel and Motor Spirit Consumption (‘000 Metric Tons), 2003-04 to 2008-09
Figure 5-1: Ethanol Production (Million Gallon), 2007 & 2008
Figure 5-2: Share in Global Ethanol Production (2008 & 2017)
Figure 5-3: Ethanol Share in Gasoline-type Fuel (2008 & 2017)
Figure 5-4: Ethanol Production Process
Figure 5-5: Ethanol Consumption (Million Gallon), 2007 & 2008
Figure 5-6: Alcohol Usage by Industry (%), 2006-07 to 2008-09
Figure 5-7: Ethanol Demand in 5% & 10% EBP (Million Liter), 2006-07 to 2008-09
Figure 5-8: Ethanol Supply (Million Liter), 2006-07 to 2009-10
Figure 5-9: Molasses Production (Million Tons), 2006-07 to 2009-10
Figure 5-10: Forecast for Ethanol Production (Million Gallon), 2009-2018
Figure 5-11: Forecast for Ethanol Consumption (Million Gallon), 2009-2018
Figure 6-1: Biodiesel Demand Potential (Million Metric Tons), 2004-05 to 2006-07
Figure 6-2: Jatropha Seeds (‘000 Tons) and Oil Production Potential (Million Liter), 2007
Figure 6-3: Cost Analysis of Biodiesel Extraction from Jatropha (Rs/Liter), 2007
Figure 6-4: Forecast for Biodiesel Demand (Million Metric Tons), 2011-12 & 2016-17
Figure 8-1: Potential Market for Flex-fuel Cars (‘000 Units), 2008-09 to 2012-13

List of Tables:

Table 3-1: Global - Biofuel Information with Feedstock Used and Blending Targets in Selected Countries
Table 3-2: Global - Biofuel Cost Analysis
Table 3-3: Global - Top Five Ethanol Producing Countries (2008)
Table 3-4: Global - Top Ten Fuel Ethanol Producing Countries (2007)
Table 4-1: Price for Crude Oil Basket (US$/Barrel), 2006-07 to 2008-09
Table 4-2: Ministries Involved in the Biofuel Sector
Table 5-1: Annual Installed Fuel Ethanol Production Capacity by State
Table 5-2: Ethanol Feedstock Comparison
Table 5-3: Cost Analysis of Ethanol Extraction from Molasses (2006-07)
Table 6-1: Jatropha Plantation by State (Hectare), 2002 to 2007

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Emerging-Biofuel-Market-in-India.html

Indian Gems and Jewellery Market - Future Prospects to 2011

India possesses world’s most competitive gems and jewellery market due to its low cost of production and availability of skilled labor. As per our new research report “Indian Gems and Jewellery Market - Future Prospects to 2011”, highly skilled and low cost manpower, along with strong government support in the form of incentives and establishment of SEZs, has been the major driver for the Indian gems and jewellery market. The market also plays a vital role in the Indian economy as it is a leading foreign exchange earner and accounts for more than 12% of India’s total exports. Currently the Indian market remains highly fragmented, but is rapidly transforming into an organized sector.

Currently, the industry is facing a slowdown due to global economic turmoil. But due to various government efforts and incentives coupled with private sector initiatives, the Indian gems and jewellery sector is expected to grow at a CAGR of around 14% from 2009 to 2012. At present, the Indian gems and jewellery market is dominated by the unorganized sector; however, the trend is set to change in near future with the branded jewellery market growing at an expected CAGR of more than 41% in the coming four years. As per our research report, with its consumption pegged at nearly 20%, India remains world’s largest gold consumer and this share is expected to grow further.

“Indian Gems and Jewellery Market - Future Prospects to 2011” provides strategic insight into the gems and jewellery market in India. By analyzing past and future aspects of the market, the report highlights the potential growth areas in the market and gives an overview on the market for gems and jewellery in the country. It also evaluates the emerging trends in the concerned industry.

Our report also covers the industry forecast and analysis based on various macro- and microeconomic factors, sector and industry specific databases, and our in-house statistical and analytical model. This model takes into account the past and current trends in an economy, and more specifically in an industry, to bring out an objective market analysis.

The information has been compiled from authentic and reliable sources like books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to over 3000 paid databases.

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Booming-Clinical-Trials-Market-in-India.html

Booming Clinical Trials Market in India

The clinical trial market in India looks very lucrative. The country promises to be one of the hottest destinations for conducting global clinical trials, owing to a huge patient pool representing both chronic and infectious diseases, easy recruitment of patients, and high cost savings. Moreover, the market is getting boost from improved IPR protection with changed rules and also from reduced taxes and duties.

According to our new research study on the sector called “Booming Clinical Trials Market in India”, the clinical trial outsourced market in India is forecasted to grow at a CAGR of around 31% during 2010-2012. Presently, the market is characterized by the dominance of phase III and phase II trials, which currently hold more than 80% of the market. This scenario is expected to remain intact in future as well. In terms of competitive landscape, the market is characterized by many small CROs, with certain companies like Syngene, Quintiles, Lambda therapeutics, Vimta labs doing better in comparison of the rest.

Our report has found that one of the biggest reasons attracting drug manufacturers and CROs to India is the country’s vast patient pool. The number of patients for chronic and infectious ailments in India surpasses that of nearly any other country. Moreover, clinical trials for drugs related to central nervous system and cancer have been mainly outsourced to India in recent years. Backed by this factor, the number of clinical studies in India is expected to grow at a CAGR of over 14% during the forecast period. In this regard, the report provides rational analysis of the factors which are supporting the forecast.

Our report provides extensive information on the clinical trial market in India, with detailed description of the regulatory environment and cost factors promoting the market. It also highlights several emerging market trends like clinical data management, pathology and diagnostic market, etc. The research study offers detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, clinical service market, key drivers and restraints. It contains all the requisite information that will help clients to draw up market strategies and assess opportunity areas in India’s clinical trial market.

Table of Contents:

1. Analyst View
2. Clinical Trials Market Overview
2.1 Global Clinical Research Market
2.2 Clinical Research Market in Asia-Pacific
2.3 Clinical Research Market in India
2.3.1 Number of Clinical Trials
2.3.2 Clinical Trials by Type
2.3.3 Clinical Research Market
2.3.4 Patient Participation
2.3.5 Market Trends
3. Size and Patient Pool Availability
3.1 Population and Demographics
3.2 Disease Profile
3.3 Patient Availability and Recruitment
4. Infrastructure and Expertise
4.1 Education
4.2 Clinical Research Professionals
4.3 Hospital Beds
4.4 ICH/GCP Compliant Sites
5. Cost Analysis
5.1 Phase I Clinical Trials
5.1.1 Cost of Staff
5.1.2 Cost of Utility
5.2 Phase II Clinical Trials
5.2.1 Cost of Infrastructure and Staff
5.2.2 Cost of Utility
5.3 Phase III Clinical Trials
5.3.1 Cost of Infrastructure and Staff
5.3.2 Cost of Utility
5.4 Phase IV Clinical Trials
5.4.1 Cost of Infrastructure and Staff
5.4.2 Cost of Utility
6. Success and Risk Factor Analysis
6.1 Lower Cost
6.2 Faster Completion
6.3 Pathology and Diagnostic Market
6.4 Clinical Data Management
6.5 Increasing Competition between Developing Countries
6.6 Demand-Supply Gap of Clinical Professionals
6.7 Long Time for Approval
7. Regulatory Environment
7.1 The Institutional Ethics Committee (IEC)
7.2 Trials that can/cannot be Conducted in India
7.3 Clinical Trials Registry
7.4 Intellectual Property Protection
7.5 Incentives Given by the Government
8. RNCOS Recommendations
9. Key Players
9.1 Syngene International Ltd
9.2 Quintiles Research (India) Private Limited
9.3 Lambda Therapeutic Research Ltd
9.4 Bioserve Clinical Research Pvt. Ltd.
9.5 Veeda Clinical Research
9.6 IGATE Clinical Research International
9.7 PharmaNet
9.8 Vimta Labs

List of Figures

Figure 2-1: Global - Number of Clinical Trials (2007-2009)
Figure 2-2: Global - Clinical Research Market (Billion US$), 2007-2009
Figure 2-3: Global - Forecast for Clinical Research Market (Billion US$), 2010-2012
Figure 2-4: Global - Clinical Research Market by Phase (%), 2008
Figure 2-5: Asia-Pacific - Share of Countries in Clinical Trial Studies (2008)
Figure 2-6: Number of Clinical Trials (2007-2009)
Figure 2-7: Forecast for Number of Clinical Trials (2010-2012)
Figure 2-8: Clinical Trials by Phase (%)
Figure 2-9: Clinical Trials by Therapy (%)
Figure 2-10: Clinical Research Market (Million US$), 2007-2009
Figure 2-11: Forecast for Clinical Research Market (Million US$), 2010-2012
Figure 2-12: Forecast for Number of Patients Participating in Clinical Trials (Million), 2010-2012
Figure 2-13: Pharma Outsourcing Market (Billion US$), 2007-2009
Figure 2-14: Pharma Outsourcing Market by Segment (%), 2008
Figure 3-1: Population (Million), 2006-2009
Figure 3-2: Forecast for Population (Million), 2010-2012
Figure 3-3: Population Breakup by Age Group (%), 2006-2009
Figure 3-4: Forecast for Population Breakup by Age Group (%), 2010-2012
Figure 3-5: Various Causes of Death (%), 2008
Figure 3-6: Forecast for Various Causes of Death (%), 2030
Figure 3-7: New and Total Number of Cancer Patients (‘000)
Figure 3-8: Number of Hypertension Patients (Million), 2000, 2007 & 2025
Figure 3-9: Number of Coronary Heart Patients (Million), 2005 & 2015
Figure 3-10: Recruitment Time for Patients Participating in Clinical Trials in Comparison to US (Days)
Figure 3-11: Number of Patient per Site in Comparison to US
Figure 4-1: Number of Individuals with Bachelor and Higher Degree (Million), 1991, 2004, 2006 & 2008
Figure 4-2: Number of Graduates and Postgraduates (Million), 2004
Figure 4-3: Share of Science Doctorates in Total Doctorates (2004)
Figure 4-4: Number of Doctors in Comparison to US and Germany (‘000), 2008
Figure 4-5: Number of Doctors (‘000), 2007-2009
Figure 4-6: Forecast for Number of Doctors (‘000), 2010-2012
Figure 4-7: Number of GCP Trained Investigators (2002 & 2005)
Figure 4-8: Number of GCP Trained Investigators in Comparison to US
Figure 4-9: Number of Hospital Beds (‘000), 2007-2009
Figure 4-10: Number of Hospital Beds in Comparison to UK, US and Germany (‘000), 2008
Figure 4-11: Forecast for Number of Hospital Beds (‘000), 2010-2012
Figure 4-12: Number of Sites for Clinical Trials in Comparison to UK, US and Germany
Figure 5-1: Average Cost per Patient for Conducting Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-2: Average Cost per Patient for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-3: Average Cost per Patient for Conducting Phase II Clinical Trials in comparison to UK, US and Germany (US$)
Figure 5-4: Annual Cost of Office Space for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-5: Average Cost per Patient for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-6: Annual Cost of Office Space for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-7: Average Cost per Patient for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-8: Annual Cost of Office Space for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 6-1: Average Cost for Conducting Various Clinical Trial Phases in Comparison to US
Figure 6-2: Time Taken for Conducting Clinical Trials by Phase in Comparison to US (Months)
Figure 6-3: Numbers of Clinical Trials Completed on Time in Comparison to UK, US and Germany
Figure 6-4: IVD Market (Million US$), 2008 & 2012
Figure 6-5: Average Time for Approval of Clinical Trials in Comparison to UK, US and Germany (Weeks)
Figure 9-1: Share of Players in Bio-services Market (2008)

List of Tables:

Table 3-1: Number of Deaths due to Various Causes (2005)
Table 3-2: Number of Diabetic Patients in Age Group 20-79 (‘000), 2007
Table 3-3: Forecast for Number of Diabetic Patients in Age Group 20-79 (‘000), 2025
Table 3-4: New Cancers Incidences (per ‘00,000 Females), 2005
Table 3-5: New Cancers Incidences (per ‘00,000 Males), 2005
Table 3-6: Prevalence of Overweight & Obesity in Males and Females (%), 2005 & 2015
Table 4-1: Structure of Medical Education
Table 4-2: Number of GLA Approved Facilities by Type
Table 5-1: Annual Cost of Staff for Conducting Phase I Clinical Trials in comparison to UK, US and Germany (US$)
Table 5-2: Annual Cost of Utility for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-3: Annual Cost of Staff for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-4: Annual Cost of Utility for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-5: Annual Cost of Staff for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-6: Annual Cost of Utility for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-7: Annual Cost of Staff for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-8: Annual Cost of Utility for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 8-1: Comparison of Factors Affecting Clinical Trials Market among Different Countries

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Booming-Clinical-Trials-Market-in-India.html

Pharmacy Retail Market - India

The pharmacy retail market is valued at INR 216 bn in 2009 and estimated to reach INR 432 bn in 2011. The market is fragmented and dominated by the unorganized sector.

The report provides a snapshot of the pharmacy retail market. Market overview gives a quick picture of the market with estimated market size, growth rate and revenue split between the organized and unorganized sector. An analysis of drivers reveals that growth in pharmaceuticals sector, increase in healthcare spending, changing disease profile, consumer attitudes, attractive margins and growth in OTC segment is driving growth in this sector. The key challenges identified include fragmented nature of Industry, lengthy supply chain, counterfeit drugs and FDI Regulations.

The report identifies the current market trends including loyalty schemes, value added services, tie-ups with retail firms, rural expansion, entry of Government in pharmacy retailing, entry of private labels, organized retailers starting pharmacy chains. The competitive landscape profiles the major players in this sector including the business description, number of stores and expansion plans for each player. The report also provides details of the key developments in this sector.

Table of Contents:

Page 1: Executive Summary
Market Overview
Page 2: Market Overview – Size and growth rate, revenue split – organized vs unorganized sector
Page 3: Store Formats
Drivers & Challenges
Page 4: Summary
Page 5- 9: Drivers
Page: 10- 12: Challenges
Trends
Page 13: Summary
Page 14-17: Trends
Government Regulations
Page 18: Drugs & Cosmetics Act 1940
Competition
Page 19: Competition Overview
Page 20-26: Major Players
Key Developments
Page 27: Key Developments

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Pharmacy-Retail-Market-India.html

The vocational training market in India is worth approximately USD 1.6 bn and is estimated to be growing at 25% per annum. Demand for skilled workers across sectors ranging from manufacturing to retail and hospitality is fuelling the market for vocational training institutes. Sustained economic growth, rising trade and burgeoning domestic demand is driving the need for workers with necessary skills.

The report begins with an overview of the industry indicating market size, growth prospects and market segmentation. The role played by the public and private sector including the governing bodies has been highlighted.  An analysis of the drivers explains growth factors such as demand for skilled labor across various industries, inefficiencies in the public education system and increasingly competitive business environment. The key challenges identified include the existing perception among individuals towards vocational training and the lack of support from financial institutions.

The major trends have been discussed which covers strategic associations between corporate and institutes, governments role encouraging public private partnerships, rise in demand for online correspondence courses and growing interest of PE/VC firms in vocational training market. The competition section highlights the major players in various fields (IT, retail, Airlines, Finance) including their business focus and expansion plans.

Table of Contents:

Page 1: Executive Summary
Overview
Page 2: Indian education system
Page 3: Public vocational training market
Page 4: Private vocational training market - Market size & growth (incl. forecast) 2008-2012
Drivers and Challenges
Page 5: Summary
Page 6-8: Drivers
Page 9-10: Challenges
Trends
Page 11: Summary
Page 12: Partnerships between corporates and training institutes
Page 13: Public Private Partnerships and demand for online training and distance learning
Page 14: Increased focus of PE/VC firms
Competition
Page 15-17: Company Snapshots
Key developments
Page 18: Key developments

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Vocational-Training-India.html

Development of WiMAX Policies and Emerging Opportunities in India

Abstract

With a broadband penetration rate of around 2% and concentration of broadband users in the urban regions, development of broadband service in India has been relatively laggard compared with its thriving mobile communications market. Therefore, India’s DoT has been aggressive towards BWA spectrum auction, hoping to thereby boost the broadband service in the country. 2.3GHz and 2.5GHz licenses are about to be auctioned soon, while 700MHz and 3.4GHz - 3.7GHz are expected to be released in the future, too. This report analyzes India’s telecom and WiMAX spectrum licensing policies as well as issues related to WiMAX equipment certification, providing insight and guidance for equipment makers seeking to tap into the Indian market.

Table of Contents:

1. India: Overall Introduction
2. India’s Telecommunications Regulatory Authorities
2.1 DoT (Department of Telecom)
2.1.1 WPC (Wireless Planning and Coordination Wing)
2.1.2 TEC (Telecommunication Engineering Centre)
2.2 TRAI (Telecommunications Regulatory Authority of India)
3. Development of India’s WiMAX Policies
3.1 India’s Telecommunications and Broadband Policies
3.2 WiMAX Spectrum Policies
3.2.1 700MHz
3.2.2 2.3GHZ and 2.5GHz
3.2.3 3.3GHz - 3.4GHz
3.2.4 3.4GHz - 3.7GHz
3.2.5 5.8GHz
3.3 Current Development of India’s WiMAX Product Certification
MIC Perspective
Appendix

List of Topics

Overall introduction to India’s current status, focusing on economic development

Profiling India’s telecommunications regulatory authorities, including DoT (Department of Telecommunications) and two subsidiaries WPC (Wireless Planning and Coordination Wing) and TEC (Telecommunication Engineering Centre), as well as independent monitoring organization TRAI (Telecommunications Regulatory Authority of India)

Analyzing the development of India’s WiMAX policies, touching upon the overall telecommunications and broadband policies, WiMAX spectrum policies, and WiMAX product specification; current uses of different frequency bands also included

Companies and organizations analyzed or mentioned in the report include:Bharti Airtel, BSNL, DishnetDSL, GTL, MTNL, Reliance Communications, Sify, Spectranet, Tata Communications

List of Tables

Table 1 Internet and Broadband User Base Targets Outlined in India’s Broadband Policy 2004
Table 2 Planned Allocation of 2.3GHz and 2.5GHz Frequency Bands in India
Table 3 Indian Carriers Awarded 3.3GHz - 3.4GHz Frequency Band
Table 4 Telecom Service Areas in India

List of Figures

Figure 1 India’s Income Structure and GDP Growth Rates
Figure 2 India’s Labor Structure by Age and Literacy Rate
Figure 3 Framework of India’s Telecom Regulatory Authorities
Figure 4 Development of India’s Telecom Policies, 1992 - 2008
Figure 5 India’s Broadband Deployment Roadmap
Figure 6 Planned Uses of 2.5GHz Frequency Band in India

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Development-of-WiMAX-Policies-and-Emerging-Opportunities-in-India.html